Search Results - "Passerini, C"

SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations by Meggendorfer, M, Bacher, U, Alpermann, T, Haferlach, C, Kern, W, Gambacorti-Passerini, C, Haferlach, T, Schnittger, S

“…Chronic myeloid malignancies are categorized to the three main categories myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDSs) and MDS/MPN…”
Get full text

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia by Khoury, H.J., Gambacorti-Passerini, C., Brümmendorf, T.H.

“…Bosutinib (SKI-606) is an oral, dual Src/Abl tyrosine kinase inhibitor (TKI) approved for treatment of patients with Philadelphia chromosome-positive (Ph+)…”
Get full text

Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications by Polverelli, N., Anghilieri, M., Elena, C., Intermesoli, T., Pungolino, E., D’Adda, M., Iurlo, A., Maffioli, M., Lunghi, F., Bertolli, V., Orofino, N., Sissa, C., Fiamenghi, C., Gardellini, A., Ubezio, M., Carraro, M. C., Corradini, P., Giglio, F., Pasquini, M. C., Palazzolo, R., Calori, R., Ercolanoni, M., Gambacorti‐Passerini, C.

“…Lombardy represents the largest region of Italy by population, with almost 10 million residents, a dimension similar to a medium size country like Sweden or…”
Get full text

Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma by Ceccon, M, Mologni, L, Giudici, G, Piazza, R, Pirola, A, Fontana, D, Gambacorti-Passerini, C

“…ALK is a tyrosine kinase receptor involved in a broad range of solid and hematologic tumors. Among 70% to 80% of ALK(+) anaplastic large cell lymphomas (ALCL)…”
Get full text

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias by Cortes, J.E, Kim, D.-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F.E, Apperley, J.F, Khoury, H.J, Talpaz, M, DiPersio, J, DeAngelo, D.J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M.C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V.M, Clackson, T, Turner, C.D, Haluska, F.G, Guilhot, F, Deininger, M.W, Hochhaus, A, Hughes, T, Goldman, J.M, Shah, N.P, Kantarjian, H

“…Several tyrosine kinase inhibitors have activity in Ph-positive chronic and acute leukemia, but resistant disease and unacceptable side effects may limit…”
Get full text

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase by Cortes, J, Kim, D-W, Raffoux, E, Martinelli, G, Ritchie, E, Roy, L, Coutre, S, Corm, S, Hamerschlak, N, Tang, J-L, Hochhaus, A, Khoury, H J, Brümmendorf, T H, Michallet, M, Rege-Cambrin, G, Gambacorti-Passerini, C, Radich, J P, Ernst, T, Zhu, C, Van Tornout, J M A, Talpaz, M

“…Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this…”
Get full text

Idiopathic erythrocytosis: a germline disease? by Elli, E. M., Mauri, M., D’Aliberti, D., Crespiatico, I., Fontana, D., Redaelli, S., Pelucchi, S., Spinelli, S., Manghisi, B., Cavalca, F., Aroldi, A., Ripamonti, A., Ferrari, S., Palamini, S., Mottadelli, F., Massimino, L., Ramazzotti, D., Cazzaniga, G., Piperno, A., Gambacorti-Passerini, C., Piazza, R.

“…Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected,…”
Get full text

Management and outcome of 11 pregnancies in women with polycythemia vera by Elli, E.M., Diral, E., Gambacorti-Passerini, C., Calori, R., Carmosino, I., Breccia, M., Latagliata, R., Di Veroli, A.

Get full text

Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: Subgroup analysis from the BELA trial by Malhotra, H., Maru, A., Khattry, N., Ramanan, M.V., Leip, E., Crescenzo, R.J., Gambacorti-Passerini, C., Cortes, J.E.

Get full text

P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER‐LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB‐ANALYSIS FROM THE PHASE 4 BYOND TRIAL by Gambacorti‐Passerini, C., Brümmendorf, T. H., Ernst, T., Leip, E., Purcell, S., Viqueira, A., Giles, F. J., Rosti, G., Hochhaus, A.

Get full text

P717: BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL by Cortes, J. E., Milojkovic, D., Gambacorti‐Passerini, C., García‐Gutiérrez, V., Mauro, M. J., Leip, E., Purcell, S., Viqueira, A., Brümmendorf, T. H.

Get full text

Are Chronic Myeloid Leukemia Patients More at Risk for Second Malignancies? A Population-based Study by Rebora, Paola, Czene, Kamila, Antolini, Laura, Passerini, Carlo Gambacorti, Reilly, Marie, Valsecchi, Maria Grazia

“…The authors used cancer registry data to assess the incidence rate of second primary cancers among chronic myeloid leukemia (CML) patients and the long-term…”
Get full text

S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT‐LEVEL META‐ANALYSIS by Kockerols, C., Dulucq, S., Bernardi, S., Farina, M., Civettini, I., Colafigli, G., Mori, S., Valk, P., Mahon, F.‐X., Gambacorti‐Passerini, C., Nicolini, F.‐E., Breccia, M., Russo, D., Westerweel, P. E.

Get full text

P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST‐IN‐CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2‐MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND‐01 TRIAL by Martinelli, G., Santoro, A., Gambacorti‐Passerini, C., Vives Polo, S., Solomon, S. R., Mukherjee, S., Lech‐Maranda, E., Yair Levy, M., Wierzbowska, A., Calbacho‐Robles, M., Marconi, G., Benedetta Giannini, M., Cano, I., Torres Miñana, L., Acuña‐Cruz, E., Angelosanto, N., Galleu, A., Baldini, S., Blotta, S., Ravandi, F., Montesinos, P.

Get full text

BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase blast crisis CML patients by Marega, M, Piazza, R G, Pirola, A, Redaelli, S, Mogavero, A, Iacobucci, I, Meneghetti, I, Parma, M, Pogliani, E M, Gambacorti-Passerini, C

“…Chronic myeloid leukemia (CML) is caused by the BCR-ABL hybrid gene. The molecular mechanisms leading from chronic phase (CP) to blast crisis (BC) are not…”
Get full text

Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells by FALANGA, A, CONSONNI, R, MARCHETTI, M, LOCATELLI, G, GARATTINI, E, GAMBACORTI PASSERINI, C, GORDON, S. G, BARBUI, T

“…All-trans-retinoic acid (ATRA) downregulates the expression of two cellular procoagulants, tissue factor (TF) and cancer procoagulant (CP), in human…”
Get full text

Synergistic activity of the Src Abl inhibitor bosutinib in combination with imatinib by Redaelli, S, Boschelli, F, Perini, P, Pirola, A, Viltadi, M, Gambacorti-Passerini, C

Get full text

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency by Ceccon, M, Merlo, M E Boggio, Mologni, L, Poggio, T, Varesio, L M, Menotti, M, Bombelli, S, Rigolio, R, Manazza, A D, Di Giacomo, F, Ambrogio, C, Giudici, G, Casati, C, Mastini, C, Compagno, M, Turner, S D, Gambacorti-Passerini, C, Chiarle, R, Voena, C

“…Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(2;5; p23;q35) that produces the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma…”
Get full text

Roots of clinical resistance to STI-571 cancer therapy by Barthe, C, Cony-Makhoul, P, Melo, J V, Mahon, J R

Get full text

Oncogenic tyrosine kinases by Gambacorti-Passerini, C

“…Tyrosine kinases (TKs) and related molecules comprise over 100 different genes. Approximately two-thirds represent receptor TKs, the other third being non…”
Get full text